Allergan intends to withdraw application filings for abicipar pegol in Europe and Japan, according to a press release from Molecular Partners.
Molecular Partners is developing the DARPin therapeutic for treatment of neovascular age-related macular degeneration.
The decision to withdraw applications to the European Medicines Agency and the Japanese Regulatory Agency follow the FDA decision to deny approval of abicipar pegol for wet AMD in the U.S. due to the rate of intraocular inflammation observed.
AbbVie, Allergan’s parent company, will continue working with the agencies regarding
Uncategorized